Roth/MKM Starts Stereotaxis (STXS) at Buy

Roth/MKM analyst Jason Wittes initiates coverage on Stereotaxis (NYSE: STXS) with a Buy rating and a price target of $5.00.

The analyst comments "We are initiating on STXS with a Buy and $5 PT. The company has developed a unique robotics platform for endovascular surgery that uses magnets to safely navigate catheters through tortuous vessels. A strong pipeline headlined by a new catheter and mobile system with approvals expected later this year will transform the business from a capital equipment dependent model to a razor/razor blade model with a much greater recurring revenue stream and significantly higher revenue base, while expanding the platform and unlocking shareholder value."

For an analyst ratings summary and ratings history on Stereotaxis click here. For more ratings news on Stereotaxis click here.

Shares of Stereotaxis closed at $1.74 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)